Legal & General Group Plc Has $16.11 Million Stake in Charles River Laboratories International, Inc. $CRL

Legal & General Group Plc grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 106,201 shares of the medical research company’s stock after purchasing an additional 11,614 shares during the period. Legal & General Group Plc owned about 0.22% of Charles River Laboratories International worth $16,114,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Exchange Traded Concepts LLC boosted its position in shares of Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after buying an additional 76 shares during the last quarter. Brooklyn Investment Group lifted its stake in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International by 1.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after acquiring an additional 86 shares during the last quarter. WESCAP Management Group Inc. grew its stake in shares of Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock worth $371,000 after acquiring an additional 89 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its stake in shares of Charles River Laboratories International by 0.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRL shares. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price target for the company from $142.00 to $195.00 in a research report on Tuesday, September 9th. Morgan Stanley boosted their target price on Charles River Laboratories International from $170.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their price target for the company from $178.00 to $199.00 in a research report on Thursday, November 6th. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Argus set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.86.

Charles River Laboratories International Trading Down 0.4%

NYSE:CRL opened at $178.14 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $203.01. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $171.68 and its 200 day moving average is $160.05. The stock has a market capitalization of $8.77 billion, a PE ratio of -133.94, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.59 earnings per share. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).